https://www.lanternpharma.com https://www.lanternpharma.com/about https://www.lanternpharma.com/our-technology https://www.lanternpharma.com/clinical-trials https://www.lanternpharma.com/collaborations https://www.lanternpharma.com/compassionate-use https://www.lanternpharma.com/contact https://www.lanternpharma.com/cookies-page https://www.lanternpharma.com/culture https://www.lanternpharma.com/lantern-careers https://www.lanternpharma.com/media https://www.lanternpharma.com/media/news https://www.lanternpharma.com/about/patent-portfolio https://www.lanternpharma.com/pipeline https://www.lanternpharma.com/about/posters https://www.lanternpharma.com/privacy-policy https://www.lanternpharma.com/about/publications https://www.lanternpharma.com/media/social-media https://www.lanternpharma.com/team https://www.lanternpharma.com/test https://www.lanternpharma.com/media/videos https://www.lanternpharma.com/media/webinars https://www.lanternpharma.com/ai-collaborations https://www.lanternpharma.com/leadership/david-r-margrave https://www.lanternpharma.com/leadership/kishor-g-bhatia-ph-d https://www.lanternpharma.com/leadership/marc-chamberlain https://www.lanternpharma.com/leadership/panna-sharma https://www.lanternpharma.com/leadership/reggie-ewesuedo https://www.lanternpharma.com/leadership/sandra-sinclair https://www.lanternpharma.com/team/david-r-margrave https://www.lanternpharma.com/team/david-silberstein-phd https://www.lanternpharma.com/team/franklyn-prendergast-m-d-ph-d https://www.lanternpharma.com/team/harry-kochat-phd https://www.lanternpharma.com/team/jeff-keyser-jd-mph-phd https://www.lanternpharma.com/team/kishor-g-bhatia-ph-d https://www.lanternpharma.com/team/michael-j-kelner-md https://www.lanternpharma.com/team/panna-sharma https://www.lanternpharma.com/team/shiv-srivastava-phd https://www.lanternpharma.com/team/vijay-chandru-ph-d https://www.lanternpharma.com/board-of-directors/david-silberstein-phd https://www.lanternpharma.com/board-of-directors/jeff-keyser-jd-mph-phd https://www.lanternpharma.com/board-of-directors/lee-schalop https://www.lanternpharma.com/board-of-directors/maria-l-maccecchini-ph-d https://www.lanternpharma.com/board-of-directors/panna-sharma https://www.lanternpharma.com/board-of-directors/vijay-chandru-ph-d https://www.lanternpharma.com/news/9-notable-ai-companies-in-clinical-research-to-watch-in-2023 https://www.lanternpharma.com/news/a-24-hour-snapshot-of-ai-drug-discovery-across-pharma-biotech-and-research https://www.lanternpharma.com/news/ai-breaches-the-barrier-towards-better-cns-drug-discovery https://www.lanternpharma.com/news/ai-cns-oncology-drug-development-lee-schalop https://www.lanternpharma.com/news/ai-is-helping-researchers-fast-track-discovering-life-saving-drugs https://www.lanternpharma.com/news/ai-ml-drug-discovery-radr https://www.lanternpharma.com/news/ai-module-predicts-cancer-combination-efficacy https://www.lanternpharma.com/news/ai-offers-promise-but-faces-barriers-in-drug-development https://www.lanternpharma.com/news/ai-platform-milestone-oncology-drug-development https://www.lanternpharma.com/news/allarity-therapeutics-lantern-pharma-enter-into-agreement-for-future-clinical-development-of-irofulven https://www.lanternpharma.com/news/artificial-intelligence-in-drug-discovery-and-biotech-2022-recap-and-key-trends https://www.lanternpharma.com/news/behind-the-powerful-computations-ais-role-in-pharma-is-still-beset-by-challenges https://www.lanternpharma.com/news/behind-the-study-retaining-nanomolar-potency-in-lung-cancer https://www.lanternpharma.com/news/benzingas-power-hour-show https://www.lanternpharma.com/news/bioboss-podcast-39-panna-sharma-ceo-of-lantern-pharma https://www.lanternpharma.com/news/biotech-is-sprouting-into-dallas-fort-worths-next-big-thing-based-on-seeds-planted-decades-ago https://www.lanternpharma.com/news/breakthrough-with-ai-powered-drug-lp-300-in-lung-cancer-treatment https://www.lanternpharma.com/news/building-a-path-to-cure-for-patients-with-nsclc-who-have-never-smoked https://www.lanternpharma.com/news/busting-the-brains-firewall-how-lantern-pharmas-algorithms-can-predict-a-drugs-ability-to-reach-the-brain https://www.lanternpharma.com/news/cost-of-care-defanged-drug-pricing-reform-means-less-of-a-bite-for-big-pharma https://www.lanternpharma.com/news/dallas-biotech-launches-open-access-ai-tool-targeting-one-of-brain-drug-discoverys-toughest-hurdles https://www.lanternpharma.com/news/dallas-firms-experimental-cancer-drug-set-to-begin-human-trials-this-summer https://www.lanternpharma.com/news/dallas-region-sees-growing-traction-around-the-life-sciences-amid-ipos-fundings https://www.lanternpharma.com/news/efa-4eb8-919c-7865be222ad4-lp-284-shows-preclinical-activity-in-atm-mutated-mcl https://www.lanternpharma.com/news/episode-68-rocking-garage-biotech https://www.lanternpharma.com/news/fda-clearance-ai-developed-lp-184-lung-cancer-trial https://www.lanternpharma.com/news/fda-grants-fast-track-designation-to-lp-184-for-glioblastoma https://www.lanternpharma.com/news/fda-grants-orphan-drug-designation-to-lp-284-for-high-grade-b-cell-lymphomas https://www.lanternpharma.com/news/fda-grants-orphan-drug-designation-to-lp-284-for-mantle-cell-lymphoma https://www.lanternpharma.com/news/fda-grants-orphan-drug-designation-to-lp-284-for-soft-tissue-sarcoma https://www.lanternpharma.com/news/fda-grants-orphan-drug-designation-to-lp-284-for-treatment-of-hgbl-with-myc-bcl2-rearrangements https://www.lanternpharma.com/news/fda-guidance-advances-lantern-pharmas-pediatric-brain-cancer-therapy-toward-2026-clinical-trial https://www.lanternpharma.com/news/fdas-elsa-ai-is-here-and-the-industry-has-questions https://www.lanternpharma.com/news/highs-and-lows-of-drug-repurposing https://www.lanternpharma.com/news/how-ai-is-expediting-medicine-development https://www.lanternpharma.com/news/how-ai-is-transforming-drug-discovery https://www.lanternpharma.com/news/how-ai-is-transforming-the-healthcare-landscape-accelerating-the-development-of-medicine https://www.lanternpharma.com/news/how-lantern-pharma-and-code-ocean-partnered-on-oncology-drug-development https://www.lanternpharma.com/news/how-lantern-pharmas-ai-is-changing-the-game https://www.lanternpharma.com/news/how-technologies-like-ai-and-machine-learning-can-help-with-the-development-of-medicine https://www.lanternpharma.com/news/lantern-ltrn-announces-filing-of-seven-patent-applications-globally-on-novel-dna-damaging-agent-with https://www.lanternpharma.com/news/lantern-pharma-actuate-therapeutics-ai-collaboration https://www.lanternpharma.com/news/lantern-pharma-advances-ai-guided-drug-into-phase-1b-2-trial-for-triple-negative-breast-cancer https://www.lanternpharma.com/news/lantern-pharma-advancing-lp-184-in-biomarker-defined-breast-lung-bladder-cancers https://www.lanternpharma.com/news/lantern-pharma-aims-to-take-drug-to-phase-3-for-100-200-million-with-ai-powered-approach https://www.lanternpharma.com/news/lantern-pharma-and-nci-expand-oncology-partnership https://www.lanternpharma.com/news/lantern-pharma-ceo-shares-his-four-secrets-to-turning-a-startup-into-an-ipo https://www.lanternpharma.com/news/lantern-pharma-collaborating-with-danish-cancer-research-center-on-drugs-for-ner-deficient-tumors https://www.lanternpharma.com/news/lantern-pharma-doses-first-patient-in-solid-tumour-drug-trial https://www.lanternpharma.com/news/lantern-pharma-establishes-new-ai-centre-of-excellence-agentic-labs-hub-in-bengaluru https://www.lanternpharma.com/news/lantern-pharma-fox-chase-partner-on-pancreatic-cancer-drug-search-for-predictive-gene-signature https://www.lanternpharma.com/news/lantern-pharma-gets-fda-nod-to-begin-phase-ii-trial-of-lp-300-in-biomarker-defined-nsclc https://www.lanternpharma.com/news/lantern-pharma-is-harnessing-the-power-of-ai-and-machine-learning-to-fight-cancer https://www.lanternpharma.com/news/lantern-pharma-is-using-artificial-intelligence-to-develop-oncology-treatments https://www.lanternpharma.com/news/lantern-pharma-launches-a-cutting-edge-ai-algorithm https://www.lanternpharma.com/news/lantern-pharma-launches-ai-tool-for-smarter-cancer-drug-pairings https://www.lanternpharma.com/news/lantern-pharma-ltrn-gets-fda-green-light-to-begin-human-trials-for-new-breast-cancer-drug https://www.lanternpharma.com/news/lantern-pharma-ltrn-reports-positive-efficacy-data-of-lp-284-in-hematologic-cancers https://www.lanternpharma.com/news/lantern-pharma-offers-ai-platform-for-adc-discovery-with-bielefeld-university https://www.lanternpharma.com/news/lantern-pharma-preparing-ind-for-synthetic-lethality-program-with-fda-feedback https://www.lanternpharma.com/news/lantern-pharma-receives-fda-clearance-of-ind-application-for-drug-candidate-lp-184-in-solid-tumors https://www.lanternpharma.com/news/lantern-pharma-releases-positive-preclinical-data-on-efficacy-of-lp-284-for-mantle-cell-lymphoma https://www.lanternpharma.com/news/lantern-pharma-rises-9-on-team-up-with-national-cancer-institute-for-drug-candidates https://www.lanternpharma.com/news/lantern-pharma-says-phase-1a-study-of-lp-184-met-all-primary-endpoints-in-advanced-solid-tumors https://www.lanternpharma.com/news/lantern-pharma-showcases-ai-platform-for-rare-cancers https://www.lanternpharma.com/news/lantern-pharma-targets-surprising-group-for-lung-cancer-screenings https://www.lanternpharma.com/news/lantern-pharma-to-study-lp-184-in-dna-damage-response-deficient-solid-tumors https://www.lanternpharma.com/news/lantern-pharma-touts-encouraging-positive-efficacy-for-pancreatic-cancer-candidate https://www.lanternpharma.com/news/lantern-pharma-transforming-oncology-drug-development-with-ai https://www.lanternpharma.com/news/lantern-pharma-unveils-ai-module-to-enhance-adc-cancer-development https://www.lanternpharma.com/news/lantern-pharmas-ai-driven-cancer-drug-lp-184-shows-promising-results-in-phase-1a-trial https://www.lanternpharma.com/news/lantern-pharmas-new-drug-candidate-for-mantle-cell-lymphoma-shows-promise https://www.lanternpharma.com/news/lantern-pharmas-new-phase-2-clinical-trial-harmonic-tm-approved-for-launch-by-the-fda https://www.lanternpharma.com/news/lantern-pharmas-pioneering-role-in-ai-driven-oncology-drug-development-with-the-radr-r-platform https://www.lanternpharma.com/news/lantern-says-ai-powered-platform-can-find-new-adc-targets-and-payloads https://www.lanternpharma.com/news/lantern-to-test-ai-developed-drug-in-triple--negative-breast-cancer-trial https://www.lanternpharma.com/news/lp-184-nsclc-nanomolar-potency https://www.lanternpharma.com/news/lp-184-phase1a-safe-effective-trial https://www.lanternpharma.com/news/lp-184-rare-pediatric-orphan-designation-atrt https://www.lanternpharma.com/news/lp-184-shows-favorable-safety-pharmacokinetics-in-advanced-solid-tumors https://www.lanternpharma.com/news/lp-284-exhibits-preclinical-efficacy-in-ddr-deficient-mcl https://www.lanternpharma.com/news/lp-300-plus-chemo-yields-early-efficacy-results-in-never-smokers-with-nsclc https://www.lanternpharma.com/news/lp-300-shows-promise-in-treating-advanced-lung-cancer-in-never-smokers https://www.lanternpharma.com/news/machine-learning-gene-signature-lp184-tumor-indications https://www.lanternpharma.com/news/midday-hot-stocks-spce-falls-as-bezos-flies-hal-ubs-rise-on-earnings-ltrn-gets-strong-pre-clinical-data https://www.lanternpharma.com/news/navigating-the-crossroads-of-ai-and-oncology-a-deep-dive-with-lantern-pharmas-ceo-panna-sharma https://www.lanternpharma.com/news/nearly-300-novel-agents-currently-in-development-for-rare-cancers https://www.lanternpharma.com/news/non-smokers-keep-getting-lung-cancer-dallas-lantern-pharma-is-using-ai-to-fight-back https://www.lanternpharma.com/news/panna-sharma-ai-cancer-therapies https://www.lanternpharma.com/news/phase-2-harmonic-trial-positive-update-nsclc https://www.lanternpharma.com/news/preclinical-data-on-new-pancreatic-cancer-drug-shines-with-over-90-efficacy https://www.lanternpharma.com/news/putting-lp-284-on-the-industry-radr https://www.lanternpharma.com/news/radr-ai-commercialization-lp184-trial-update https://www.lanternpharma.com/news/radr-ai-platform-reaches-4-6b-datapoints https://www.lanternpharma.com/news/slice-of-healthcare-podcast-192-panna-sharma-ceo-president-at-lantern-pharma https://www.lanternpharma.com/news/study-finds-new-synthetic-lethal-agent-could-be-potential-treatment-for-pancreatic-cancer https://www.lanternpharma.com/news/technology-is-rapidly-changing-cancer-care https://www.lanternpharma.com/news/the-ai-pharmacist https://www.lanternpharma.com/news/the-local-oncology-innovator-smashing-drug-development-timelines https://www.lanternpharma.com/news/the-trends-that-will-shape-the-biotech-industry-in-2024 https://www.lanternpharma.com/news/this-pharma-company-is-using-machine-learning-and-ai-to-attempt-to-transform-oncology-drug-development-processes https://www.lanternpharma.com/news/unveiling-lantern-pharmas-success-story-in-ai-powered-precision-oncology https://www.lanternpharma.com/news/using-ai-in-the-development-of-novel-adcs-lantern-pharma-and-bielefeld-university-to-cooperate https://www.lanternpharma.com/news/what-going-public-means-for-lantern-pharma https://www.lanternpharma.com/news/what-is-the-real-cost-of-developing-medicine https://www.lanternpharma.com/news/why-we-are-on-the-cusp-of-a-golden-age-of-medicine https://www.lanternpharma.com/news/world-cancer-day-innovation-in-the-cancer-treatment-pipeline https://www.lanternpharma.com/advisors/harry-kochat-phd https://www.lanternpharma.com/advisors/michael-j-kelner-md https://www.lanternpharma.com/advisors/shiv-srivastava-phd